Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease:: basis for the in vitro screening of anti-SARS drugs

被引:39
作者
Lin, CW [1 ]
Tsai, CH
Tsai, FJ
Chen, PJ
Lai, CC
Wan, L
Chiu, HH
Lin, KH
机构
[1] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung 404, Taiwan
[2] China Med Univ Hosp, Dept Med Genet & Med Res, Taichung 404, Taiwan
[3] China Med Univ Hosp, Dept Lab Med, Clin Virol Lab, Taichung 404, Taiwan
[4] Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Taipei 100, Taiwan
关键词
SARS-coronavirus; 3C-like protease; trans- and cis-cleavaae; substrate specificity;
D O I
10.1016/j.febslet.2004.08.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Severe acute respiratory syndrome (SARS) has been globally reported. A novel coronavirus (CoV), SARS-CoV, was identified as the etiological agent of the disease. SARS-CoV 3C-like protease (3CL(pro)) mediates the proteolytic processing of replicase polypeptides la and lab into functional proteins, playing an important role in viral replication. In this study, we demonstrated the expression of the SARS-CoV 3CL(pro) in Escheichia coli and Vero cells, and then characterized the in vitro trans-cleavage and the cell-based cis-cleavage by the 3CL(pro). Mutational analysis of the 3CL(pro) demonstrated the importance of His41, Cys145, and Glu166 in the substrate-binding subsite SI for keeping the proteolytic activity. In addition, alanine substitution of the cleavage substrates indicated that Gln-(p1) in the substrates mainly determined the cleavage efficiency. Therefore, this stud), not only established the quantifiable and reliable assay for the in vitro and cell-based measurement of the 3CL(pro) activity, but also characterized the molecular interaction of the SARS-CoV 3CL(pro) with the substrates. The results will be useful for the rational development of the anti-SARS drugs. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 21 条
[1]   Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].
Anand, K ;
Ziebuhr, J ;
Wadhwani, P ;
Mesters, JR ;
Hilgenfeld, R .
SCIENCE, 2003, 300 (5626) :1763-1767
[2]   Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain [J].
Anand, K ;
Palm, GJ ;
Mesters, JR ;
Siddell, SG ;
Ziebuhr, J ;
Hilgenfeld, R .
EMBO JOURNAL, 2002, 21 (13) :3213-3224
[3]   Identification of a novel coronavirus in patients with severe acute respiratory syndrome [J].
Drosten, C ;
Günther, S ;
Preiser, W ;
van der Werf, S ;
Brodt, HR ;
Becker, S ;
Rabenau, H ;
Panning, M ;
Kolesnikova, L ;
Fouchier, RAM ;
Berger, A ;
Burguière, AM ;
Cinatl, J ;
Eickmann, M ;
Escriou, N ;
Grywna, K ;
Kramme, S ;
Manuguerra, JC ;
Müller, S ;
Rickerts, V ;
Stürmer, M ;
Vieth, S ;
Klenk, HD ;
Osterhaus, ADME ;
Schmitz, H ;
Doerr, HW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) :1967-1976
[4]  
ENJUANES L, 2000, VIRUS TAXONOMY
[5]   Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase [J].
Fan, KQ ;
Wei, P ;
Feng, Q ;
Chen, SD ;
Huang, CK ;
Ma, L ;
Lai, B ;
Pei, JF ;
Liu, Y ;
Chen, JG ;
Lai, LH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (03) :1637-1642
[6]   Prediction of proteinase cleavage sites in polyproteins of coronaviruses and its applications in analyzing SARS-CoV genomes [J].
Gao, F ;
Ou, HY ;
Chen, LL ;
Zheng, WX ;
Zhang, CT .
FEBS LETTERS, 2003, 553 (03) :451-456
[7]   Conservation of substrate specificities among coronavirus main proteases [J].
Hegyi, A ;
Ziebuhr, J .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :595-599
[8]  
HOLMES KV, 2001, FIELDS VIROLOGY
[9]   Patient data, early SARS epidemic, Taiwan [J].
Hsueh, PR ;
Chen, PJ ;
Hsiao, CH ;
Yeh, SH ;
Cheng, WC ;
Wang, JL ;
Chiang, BL ;
Chang, SC ;
Chang, FY ;
Wong, WW ;
Kao, CL ;
Yang, PC .
EMERGING INFECTIOUS DISEASES, 2004, 10 (03) :489-493
[10]  
Hsueh PR, 2003, EMERG INFECT DIS, V9, P1163